A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: ...

BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available ...

Immutep (IMMP) stock plummeted 80% after the company halted its Phase III NSCLC trial for futility, triggering analyst downgrades and massive selling.

Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

Amid concerns about flight restrictions over President Trump's Mar-a-Lago, the Citizens' Committee on Airport Noise will review monitor locations.

Officials hope to collect data on noise from planes diverted away from President Donald Trump's Mar-a-Lago Club in Palm Beach.

Kivo reports that the journey of prescription drugs involves extensive research, clinical trials, regulatory reviews, and ...

Party-line votes cast by members of the Pennsylvania House Energy Committee on Monday advanced a pair of bills proposing an ...

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with follicular lymphoma and epithelioid sarcoma.

Add Yahoo as a preferred source to see more of our stories on Google. Under a bill advanced Thursday, data centers and other power-hungry projects would pay for more of the infrastructure upgrades ...